Kezar Life Sciences

 

About KZR-616

KZR-616, which is the investigational drug in this study, is a selective immunoproteasome inhibitor. The immunoproteasome is found inside cells of the immune system and is responsible for breaking down various proteins in these cells. By blocking protein breakdown, laboratory research has indicated that KZR-616 can reduce the inflammation and autoimmune processes that underly diseases like LN. We believe that KZR-616 may have broad therapeutic potential across multiple autoimmune diseases, while having the potential to avoid immunosuppression.  

 

Who is Eligible for this Study?


To be considered eligible for the MISSION study participants must:

  • Be between the ages of 18 and 75 years of age
  • Have lupus nephritis that has been confirmed by biopsy
    (or willing to have confirmed by biopsy)
  • Have proteinuria (protein spilling into the urine)
  • Are on or willing to go on stable doses of corticosteroids (steroids)
    and CellCept® (mycophenolate mofetil or MMF), Myfortic®
    (mycophenolic acid or MPA), or Cytoxan ® (cyclophosphamide)

Participants must meet other study criteria to take part in the MISSION Study.

For more information, please contact clinicaltrials@kezarbio.com or see the full list of eligibility criteria at ClinicalTrials.gov


  

Certain links within this site connect to other websites maintained by third parties over whom CADF has no control. CADF makes no representations as to the accuracy or any other aspect of information contained in other websites.


Providing these links does not imply any endorsement, non-endorsement, support or commercial gain by CADF. 

image4